

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5203236

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ACENDA PHARMA, INC.	10/16/2018
RECEIVING PARTY DATA	
Name:	ENROCK PHARMACEUTICAL TECHNOLOGIES (HEBEI) LIMITED
Street Address:	226 HUANGHE AVENUE
Internal Address:	HEBEI
City:	SHIJIAZHUANG
State/Country:	CHINA
Postal Code:	050035
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	9695138
Patent Number:	9850219
PCT Number:	US2017051641
CORRESPONDENCE DATA	
Fax Number:	(617)937-2400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 937-2325
Email:	fvandermaelen@cooley.com
Correspondent Name:	COOLEY LLP, ATTN: PATENT GROUP
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	ACPH-001
NAME OF SUBMITTER:	HEIDI A. ERLACHER
SIGNATURE:	/Heidi A. Erlacher/
DATE SIGNED:	10/24/2018
Total Attachments: 4	
source=ACPH-001 - Assignment#page1.tif	
source=ACPH-001 - Assignment#page2.tif	

source=ACPH-001 - Assignment#page3.tif

source=ACPH-001 - Assignment#page4.tif

ASSIGNMENT OF PATENT RIGHTS
(Company to Company)

Acenda Pharma, Inc., a corporation having its principal place of business at 11840 NW 11th Place, Coral Springs, FL 33071 (herein referred to as "Assignor") owns the entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth below, as well as any invention(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

Letters Patent(s)

Patent No.: 9,695,138

Issue Date: July 4, 2017

Title: PHENOTHIAZINE DERIVATIVES AND METHODS OF USE THEREOF

Patent No.: 9,850,219

Issue Date: December 26, 2017

Title: PHENOTHIAZINE DERIVATIVES AND METHODS OF USE THEREOF

PCT Patent Application

PCT Patent Application No.: PCT/US2017/051641 Issue Date: September 14, 2017

Title: PHENOTHIAZINE DERIVATIVES AND METHODS OF USE THEREOF

WHEREAS, Enrock Pharmaceutical Technologies (Hebei) Limited, a corporation having its principal place of business at 226 Huanghe Avenue, Hebei, Shijiazhuang 050035, PEOPLE'S REPUBLIC OF CHINA its successors, legal representatives and assigns (the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any application(s), the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to said invention(s), and application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), including divisions, continuations, and continuations-in-part of said application(s), the right to

recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), the entire right, title and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s), the entire right, title and interest in and to any and all reissues and extensions of said patent(s), and all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignor is the sole and lawful owner of the entire right, title and interest in and to said invention(s), said application(s), and said patent(s), and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention(s), said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 10/16/18

By: Haiping Cheng
Name: Haiyung Cheng
Title: President
Company: Acenda Pharma, Inc.


Witness:

10/16/18
Date
10/16/18
Date

鄧海波
張紅芳

For and on behalf of ASSIGNEE:

Date: 10/17/2018

By: 

Name:

Title:

Company: Enrock Pharmaceutical
Technologies (Hebei) Limited